Open AccessAssessment of Her-2/neu gene amplification status in breast carcinoma with equivocal 2+ Her-2/neu immunostaining
Author(s) -
Naglaa A. Mostafa,
Sanaa Eissa,
Dalia M. Belal,
Soheir Shoman
Publication year - 2011
Publication title -
journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2011.07.006
Subject(s) - medicine , immunostaining , her2/neu , breast carcinoma , gene duplication , pathology , oncology , breast cancer , gene , cancer research , immunohistochemistry , cancer , genetics , biology
Amplification of Her-2/neu gene occurs in 25-30% of breast carcinomas. FDA approved trastuzumab (Herceptin) is effective only in tumors having the gene amplification. Immunohistochemistry (IHC) for Her-2/neu protein is widely used but false positive and false negative results exist. Fluorescence in-situ hybridization (FISH) has both excellent sensitivity and specificity in detecting Her-2/neu amplification. Comparative studies have shown discordant results in proportion of cases with equivocal 2+ immunostain. This study is thus conducted to ascertain the frequency of Her-2/neu gene amplification by FISH in breast carcinoma specified as score 2+ by IHC and to correlate these findings with parameters of prognosis in breast cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom